Roberto Arrojo

516 total citations
11 papers, 392 citations indexed

About

Roberto Arrojo is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Roberto Arrojo has authored 11 papers receiving a total of 392 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Molecular Biology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Roberto Arrojo's work include Monoclonal and Polyclonal Antibodies Research (4 papers), Radiopharmaceutical Chemistry and Applications (3 papers) and HER2/EGFR in Cancer Research (3 papers). Roberto Arrojo is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (4 papers), Radiopharmaceutical Chemistry and Applications (3 papers) and HER2/EGFR in Cancer Research (3 papers). Roberto Arrojo collaborates with scholars based in United States. Roberto Arrojo's co-authors include David M. Goldenberg, Thomas M. Cardillo, Robert M. Sharkey, Chien‐Hsing Chang, Preeti Trisal, Donglin Liu, Serengulam V. Govindan, Edmund A. Rossi, Diane L. Rossi and Sung-Ju Moon and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and Bioconjugate Chemistry.

In The Last Decade

Roberto Arrojo

11 papers receiving 376 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roberto Arrojo United States	5	308	148	133	95	36	11	392
Anna Shvartsur United States	5	194 0.6×	69 0.5×	124 0.9×	65 0.7×	33 0.9×	6	317
Jarob Saker Germany	6	193 0.6×	121 0.8×	157 1.2×	113 1.2×	26 0.7×	7	322
Veronica Bonasera Italy	5	228 0.7×	66 0.4×	152 1.1×	73 0.8×	44 1.2×	5	375
Kaisa Erjala Finland	7	218 0.7×	58 0.4×	158 1.2×	135 1.4×	36 1.0×	8	340
Ron Korn United States	8	206 0.7×	71 0.5×	104 0.8×	68 0.7×	83 2.3×	26	350
Lydia Koi Germany	10	144 0.5×	84 0.6×	154 1.2×	112 1.2×	150 4.2×	19	375
Sarah E. Dorff United States	4	177 0.6×	96 0.6×	117 0.9×	57 0.6×	60 1.7×	5	364
Claudia Bodenstein Germany	6	132 0.4×	177 1.2×	112 0.8×	141 1.5×	74 2.1×	6	354
Yoshikane Nonagase Japan	11	390 1.3×	185 1.3×	125 0.9×	204 2.1×	103 2.9×	19	515
Takuo Takehana Japan	7	338 1.1×	120 0.8×	140 1.1×	224 2.4×	43 1.2×	14	478

Countries citing papers authored by Roberto Arrojo

Since Specialization

Citations

This map shows the geographic impact of Roberto Arrojo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Arrojo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Arrojo more than expected).

Fields of papers citing papers by Roberto Arrojo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roberto Arrojo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Arrojo. The network helps show where Roberto Arrojo may publish in the future.

Co-authorship network of co-authors of Roberto Arrojo

This figure shows the co-authorship network connecting the top 25 collaborators of Roberto Arrojo. A scholar is included among the top collaborators of Roberto Arrojo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roberto Arrojo. Roberto Arrojo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Cardillo, Thomas M., Roberto Arrojo, Robert M. Sharkey, et al.. (2024). Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas. Oncotarget. 15(1). 144–158. 9 indexed citations

Cardillo, Thomas M., Diane L. Rossi, Donglin Liu, et al.. (2020). Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer. Oncotarget. 11(43). 3849–3862. 32 indexed citations

Cardillo, Thomas M., et al.. (2017). Synthetic Lethality Exploitation by an Anti–Trop-2-SN-38 Antibody–Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2 –wild-type Triple-Negative Breast Cancer. Clinical Cancer Research. 23(13). 3405–3415. 98 indexed citations

Goldenberg, D M, et al.. (2016). Abstract P6-15-02: Synthetic lethality in TNBC mediated by an anti-Trop-2 antibody-drug conjugate, sacituzumab govitecan (IMMU-132), when combined with paclitaxel or the PARP inhibitor, olaparib. Cancer Research. 76(4_Supplement). P6–15. 1 indexed citations

Cardillo, Thomas M., et al.. (2016). Abstract 584: Significant enhancement of efficacy of an anti-Trop-2 antibody-drug conjugate, sacituzumab govitecan (IMMU-132), in experimental triple-negative breast cancer (TNBC) when combined with microtubule or PARP inhibitors. Cancer Research. 76(14_Supplement). 584–584. 2 indexed citations

Cardillo, Thomas M., et al.. (2015). Abstract C166: Combining an anti-Trop-2 antibody-SN-38 conjugate (sacituzumab govitecan) with microtubule inhibitors (paclitaxel and eribulin mesylate) or PARP inhibitor (olaparib) significantly improves therapeutic outcome in experimental triple-negative breast cancer (TNBC). Molecular Cancer Therapeutics. 14(12_Supplement_2). C166–C166. 1 indexed citations

Cardillo, Thomas M., Serengulam V. Govindan, Robert M. Sharkey, et al.. (2015). Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjugate Chemistry. 26(5). 919–931. 209 indexed citations

Cardillo, Thomas M., Preeti Trisal, Roberto Arrojo, David M. Goldenberg, & Chien‐Hsing Chang. (2013). Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro. BMC Cancer. 13(1). 170–170. 28 indexed citations

Govindan, Serengulam V., Thomas M. Cardillo, Fatma Tat, et al.. (2012). Abstract 2526: Optimal cleavable linker for antibody-SN-38 conjugates for cancer therapy: Impact of linker's stability on efficacy. Cancer Research. 72(8_Supplement). 2526–2526. 4 indexed citations

10.

Moon, Sung-Ju, Fatma Tat, Roberto Arrojo, et al.. (2010). Abstract 2439: Cross-linker evaluation in the design of antibody-SN-38 conjugates for cancer therapy. Cancer Research. 70(8_Supplement). 2439–2439. 4 indexed citations

11.

Cardillo, Thomas M., Edmund A. Rossi, Roberto Arrojo, et al.. (2010). Abstract 5346: A novel immunotoxin comprising quadruple RNase tethered to an internalizing anti-TROP-2 humanized MAb shows potent cytotoxicity against diverse solid tumors in vitro. Cancer Research. 70(8_Supplement). 5346–5346. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact